RxDoctor Payments Data

Sean Epps, PA

Physician Assistant · Rocky Mount, NCNPI 1184625303

Payments from drug & device makers

$734in general payments, 2019–2025

Across 30 payments — averaging $24.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$214
  • Novo Nordisk$175
  • Lilly USA, LLC$125
  • Axsome Therapeutics, Inc.$120
  • AbbVie$38
  • Pfizer$26
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$734100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$734 in reported general payments places this provider in the 65th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$119,603
Medicare patients
309
Services billed
3,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide134$167,889
EliquisApixaban169$145,847
TrulicityDulaglutide90$128,861
JardianceEmpagliflozin114$101,583
LinzessLinaclotide74$72,438
OzempicSemaglutide63$71,478
Trelegy ElliptaFluticasone/Umeclidin/Vilanter84$64,263
JanuviaSitagliptin Phosphate62$51,441
FarxigaDapagliflozin Propanediol43$44,748
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog52$42,398
Tresiba Flextouch U-100Insulin Degludec49$36,371
Breo ElliptaFluticasone/Vilanterol64$28,621
XifaxanRifaximin14$28,257
SymbicortBudesonide/Formoterol Fumarate84$23,668
TradjentaLinagliptin27$22,549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$175$239,367197 claims
Lilly USA, LLCTrulicity, Mounjaro$125$150,354109 claims
PfizerEliquis$26$145,847169 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere, Lokelma, Brilinta$214$122,204213 claims
AbbVieLinzess$38$72,43874 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Rocky Mount

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →